Study #2019-0943
Neoadjuvant immune checkpoint blockade in Resectable Malignant Pleural Mesothelioma
MD Anderson Study Status
Not Accepting
Treatment Agent
Nivolumab Injection, Ipilimumab Injection
Description
The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1 year following completion of standard bi-/tri-modality therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mesothelioma
Study phase:
Phase II
Physician name:
Reza Mehran
Department:
Thoracic & Cardiovascular Surgery
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.